The global brain implants market accounted for USD 6.00 billion in 2023 and is expected to reach at USD 16.67 billion by 2034 with a CAGR of 9.73% during the forecast period 2024-2034. The growing acceptance of brain stimulation therapies, growing awareness of brain implants, increasing technological advancements, growing prevalence of neurological disorders, and an increase in strategic alliances and collaborations will all contribute to the market's growth.
Globally, neurological conditions such as depression, epilepsy, Parkinson's disease, and Alzheimer's disease are on the rise. Since these disorders are more common in older persons, this is partially attributable to the aging of the population. Demand for brain implant therapies will increase in tandem with the rise in the number of persons suffering from neurological illnesses. For instance, Medtronic plc announced in February 2024 that the FDA had approved their new DBS system with directed leads, which provides more accurate stimulation for Parkinson's disease.
By product, the deep brain stimulator segment accounted for the highest revenue-grossing segment in the global brain implants market in 2023 owing to the high efficacy of deep brain stimulation therapy in managing symptoms of Parkinson's disease, essential tremor, and other neurological disorders, coupled with increasing adoption of this technology by healthcare providers and patients worldwide. For instance, Abbott Laboratories presented studies on the use of their DBS system for treatment-resistant depression at a neurostimulation conference in January 2024. Additionally, the vagus nerve stimulator segment is predicted to grow at the fastest CAGR during the forecast period owing to the growing recognition of its effectiveness in treating epilepsy, depression, and other neurological conditions, along with advancements in device technology and expanding applications beyond traditional indications.
By application, the chronic pain segment accounted for the highest revenue-grossing segment in the global brain implants market in 2023 owing to the increasing prevalence of chronic pain conditions worldwide, coupled with the efficacy of brain implants in providing long-term relief and the growing acceptance of neuromodulation therapies among patients and healthcare professionals. For instance, in January 2024, Abbott Laboratories presented findings at a neurostimulation conference on using its DBS system for treatment-resistant depression. Additionally, the Parkinson’s segment is predicted to grow at the fastest CAGR during the forecast period owing to the rising prevalence of Parkinson's disease globally, coupled with advancements in deep brain stimulation technology and increasing adoption of surgical interventions for symptom management among patients and healthcare providers.
By end-user, the hospital's segment accounted for the highest revenue-grossing segment in the global brain implants market in 2023 owing to the increasing number of surgical procedures performed in hospitals, coupled with the availability of advanced infrastructure and expertise required for implantation and management of brain implant devices. For instance, in October 2023, Precision Neuroscience Corporation acquired a manufacturing site in Dallas for the fabrication of the core components of their brain implants Additionally, the specialty clinics segment is predicted to grow at the fastest CAGR during the forecast period owing to the rising demand for specialized care and personalized treatment options for neurological disorders, along with the increasing establishment of dedicated clinics offering brain implantation services and post-operative care.
North American region is anticipated to have the highest revenue share during the forecast period owing to the strong presence of key market players, high healthcare expenditure, advanced healthcare infrastructure, and increasing prevalence of neurological disorders driving the adoption of brain implant technologies in the region. Additionally, the Asia Pacific region is predicted to grow at the fastest CAGR during the forecast period owing to the rapidly expanding healthcare infrastructure, increasing prevalence of neurological disorders, growing awareness about brain implant therapies, and rising investments in research and development activities in the region. For instance, in August 2023, Neuralink, an Abram implant business, raised USD 280.0 million for the development of its US FDA-approved technology and plans to conduct human clinical studies shortly.
This extensive research report concentrates on the size and projections of the global and regional markets from 2023 to 2034.
Globally, neurological conditions such as depression, epilepsy, Parkinson's disease, and Alzheimer's disease are on the rise. Since these disorders are more common in older persons, this is partially attributable to the aging of the population. Demand for brain implant therapies will increase in tandem with the rise in the number of persons suffering from neurological illnesses. For instance, Medtronic plc announced in February 2024 that the FDA had approved their new DBS system with directed leads, which provides more accurate stimulation for Parkinson's disease.
By product, the deep brain stimulator segment accounted for the highest revenue-grossing segment in the global brain implants market in 2023 owing to the high efficacy of deep brain stimulation therapy in managing symptoms of Parkinson's disease, essential tremor, and other neurological disorders, coupled with increasing adoption of this technology by healthcare providers and patients worldwide. For instance, Abbott Laboratories presented studies on the use of their DBS system for treatment-resistant depression at a neurostimulation conference in January 2024. Additionally, the vagus nerve stimulator segment is predicted to grow at the fastest CAGR during the forecast period owing to the growing recognition of its effectiveness in treating epilepsy, depression, and other neurological conditions, along with advancements in device technology and expanding applications beyond traditional indications.
By application, the chronic pain segment accounted for the highest revenue-grossing segment in the global brain implants market in 2023 owing to the increasing prevalence of chronic pain conditions worldwide, coupled with the efficacy of brain implants in providing long-term relief and the growing acceptance of neuromodulation therapies among patients and healthcare professionals. For instance, in January 2024, Abbott Laboratories presented findings at a neurostimulation conference on using its DBS system for treatment-resistant depression. Additionally, the Parkinson’s segment is predicted to grow at the fastest CAGR during the forecast period owing to the rising prevalence of Parkinson's disease globally, coupled with advancements in deep brain stimulation technology and increasing adoption of surgical interventions for symptom management among patients and healthcare providers.
By end-user, the hospital's segment accounted for the highest revenue-grossing segment in the global brain implants market in 2023 owing to the increasing number of surgical procedures performed in hospitals, coupled with the availability of advanced infrastructure and expertise required for implantation and management of brain implant devices. For instance, in October 2023, Precision Neuroscience Corporation acquired a manufacturing site in Dallas for the fabrication of the core components of their brain implants Additionally, the specialty clinics segment is predicted to grow at the fastest CAGR during the forecast period owing to the rising demand for specialized care and personalized treatment options for neurological disorders, along with the increasing establishment of dedicated clinics offering brain implantation services and post-operative care.
North American region is anticipated to have the highest revenue share during the forecast period owing to the strong presence of key market players, high healthcare expenditure, advanced healthcare infrastructure, and increasing prevalence of neurological disorders driving the adoption of brain implant technologies in the region. Additionally, the Asia Pacific region is predicted to grow at the fastest CAGR during the forecast period owing to the rapidly expanding healthcare infrastructure, increasing prevalence of neurological disorders, growing awareness about brain implant therapies, and rising investments in research and development activities in the region. For instance, in August 2023, Neuralink, an Abram implant business, raised USD 280.0 million for the development of its US FDA-approved technology and plans to conduct human clinical studies shortly.
This extensive research report concentrates on the size and projections of the global and regional markets from 2023 to 2034.
Report Scope:
- Base Year: 2023
- Forecast Period: 2024-2034
- Study Coverage
- Market Forecast by Product, Application, and End-User
- Market Forecast for 5 Regions and 17+ Countries
- North America (U.S. and Canada)
- Europe (Germany, France, UK, Spain, Italy, Russia, Rest of Europe)
- Asia Pacific (China, Japan, India, Australia, South Korea, Rest of APAC)
- Latin America (Brazil, Mexico, Argentina, Rest of LATAM)
- MEA (South Africa, GCC, Rest of MEA)
- Exhaustive Company Profiles of the Top 10+ Major Market Players
Segmentation: Brain Implants Market Report 2023 - 2034
Brain Implants Market Analysis & Forecast by Product 2023 - 2034 (Revenue USD Bn)
- Deep Brain Stimulator
- Spinal Cord Stimulator
- Vagus Nerve Stimulator
Brain Implants Market Analysis & Forecast by Application 2023 - 2034 (Revenue USD Bn)
- Chronic pain
- Epilepsy
- Parkinson's
- Depression
- Essential Tremor
- Alzheimer’s
Brain Implants Market Analysis & Forecast by End-User 2023 - 2034 (Revenue USD Bn)
- Hospitals
- Specialty Clinics
- Others
Brain Implants Market Analysis & Forecast by Region 2023 - 2034 (Revenue USD Bn)
- North America
- U.S.
- Canada
- Europe
- Germany
- France
- UK
- Spain
- Italy
- Rest of Europe
- Asia Pacific
- China
- Japan
- India
- Australia
- South Korea
- Rest of APAC
- Latin America
- Brazil
- Mexico
- Argentina
- Rest of LATAM
- Middle East & Africa
- South Africa
- GCC
- Rest of MEA
Table of Contents
1. Research Methodology
2. Introduction
4. Market Environment Analysis
5. Market Dynamics
7. Brain Implants Market: Product Estimates & Trend Analysis
8. Brain Implants Market: Application Estimates & Trend Analysis
9. Brain Implants Market: End-User Estimates & Trend Analysis
10. Regional Market Analysis
11. North America Brain Implants Market
12. Europe Global Brain Implants Market
13. Asia Pacific Global Brain Implants Market
14. Latin America Global Brain Implants Market
15. MEA Global Brain Implants Market
16. Competitor Analysis
17. Company Profiles
Companies Mentioned
- Medtronic plc
- Abbott Laboratories (formerly St. Jude Medical Inc.)
- Boston Scientific Corporation
- LivaNova PLC
- NeuroPace Inc.
- Nevro Corp.
- Synapse Biomedical Inc.
- Soterix Medical Inc.
- NeuroSigma Inc.
- Nevro Corp.
- NeuroPace Inc.
- Aleva Neurotherapeutics SA
- MicroPort Scientific Corporation
- NDI Medical LLC (acquired by Greatbatch Inc.)
- Neuronetics Inc.
